Clinical Trial Update: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Caelyx (pegylated liposomal doxorubicin) to paclitaxel HCl in epithelial ovarian carcinoma after failure of first-line platinum-based …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Paclitaxel HCl (paclitaxel)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Ovarian Neoplasms | Phase 3 | Status: TERMINATED